Poster discussion sessions
AM14_ProgramBook_800x317.jpg

Poster discussion sessions


Saturday, March 22

Pearls from the posters: New and noteworthy research finds

Learning objectives: Analyze new therapeutics in the pipeline and methods of predicting response to treatment; evaluate associations that suggest evaluation for coexistent disease

Moderator: Lorraine Rosamilia, MD

Date/time: Saturday, March 22 from 7:15 a.m. to 8:45 a.m.

7805: Erythroderma: Searching for diagnostic clues in a series of 164 patients.

7885: Interleukin 33 is differentially expressed in psoriasis-like drug reactions to TNF antagonists.

8324: Melanoma associated with TNFa inhibitors: A research on adverse drug reactions (RADAR) report.

8398: Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.

7571: Immunohistochemical detection of BRAF mutation in melanoma.

7622: A population-based study on the association between bullous pemphigoid and neurologic disease.

7657: Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis.

8033: Secukinumab efficacy in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: A subanalysis of the ERASURE study.


Monday, March 24

Pearls from the posters: Top case studies and reports

Learning objectives: Recognize uncommon or new diagnoses; analyze case reports and studies for clues to pathophysiology, treatment options, and outcomes.

Moderator: Lindsay Eminger, MD

Date/time: Monday, March 24 from 7:15 a.m. to 8:45 a.m.

7596: Vismodegib induced amenorrhea: Mechanism of FSH blockade and implication for tumor angiogenesis.

8583: Intravascular large B-cell lymphoma: Report of a case and review of the literature.

7869: Rothmund-Thomson Syndrome. A 13-year follow-up.

8313: Drug-induced skin pigmentation: Three cases to report.

8346: Psoriasiform eruption in the setting of West Nile virus.

8428: Folliculotropic mycosis fungoides: Eight cases report.

8657: Demodex inflammatory eruption due to EGFR inhibitor therapy.

 




Meeting News

Follow coverage of the Annual Meeting on the AAD Meeting News website.